Published in AIDS Weekly, December 7th, 1998
Science is now on the verge of a major breakthrough in understanding the regulation of cellular immunity. Ligands capable of partially activating T cells - known as altered peptide ligands (APL), TCR partial agonists, or TCR antagonists - have for the first time been demonstrated in vivo.
Whether such ligands play a major or minor role in cellular immunity remains to be seen, but the new findings move this field of inquiry out of culture dishes and into animal models.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.